Corium is a commercial-stage biopharmaceutical company leading the development of novel transdermal healthcare products that are intended to provide alternative treatment options for patients and their families.
We are innovators focused on developing, manufacturing and commercializing specialty CNS pharmaceuticals from our own pipeline.
We are seeking FDA approval of our lead investigational product, Corplex™ Donepezil, as a once-weekly transdermal patch containing the active ingredient in Aricept® (donepezil hydrochloride) for the treatment of patients with mild, moderate and severe Alzheimer’s disease.
Collaborating with some of the world’s largest pharmaceutical and consumer product companies, we have a track record of taking products from concept through development to commercial manufacturing.
Corium’s transdermal technologies are designed to deliver both small and large molecule therapeutics, potentially enabling the development of innovative novel products that could provide significant clinical and commercial advantages, including valuable product lifecycle management.
The safety and efficacy of the products under investigation have not been established. There is no assurance that any of these investigational products will receive health authority approval or become commercially available in any country.